Every Form 4 that Alamar Biosciences, Inc. (ALMR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALMR filings page.
Alamar Biosciences, Inc. (ALMR) reported that director Robert P. Ragusa received equity awards on September 1, 2026. He was granted 5,686 restricted stock units, which vest in equal annual installments over three years starting September 1, 2026, subject to his continuous service. He also received a stock option for 25,599 shares of common stock at an exercise price of $29.36 per share, expiring August 31, 2036; one-third of these option shares vest on September 1, 2027, with the remainder vesting in equal monthly installments through September 1, 2029, contingent on continued service. Following these grants, he holds 5,686 shares of common stock directly and 25,599 option shares related to this award, and no Rule 10b5-1 trading plan is reported.
Alamar Biosciences, Inc. reported that investment vehicles affiliated with Qiming converted multiple series of preferred stock into equity tied to its initial public offering. Qiming-related funds converted Series A-3, Series A-4, Series B and Series C preferred stock into Class B Common Stock, and each Class B share was then automatically reclassified into Common Stock immediately before the IPO.
All transactions were indirect, recorded at a price of $0.00 per share, and coded as conversions or other internal restructurings rather than market purchases or sales. The Qiming general partner entities may be deemed to share voting and dispositive power but disclaim beneficial ownership beyond their proportionate economic interest.
Alamar Biosciences, Inc. reported insider activity by entities affiliated with the Illumina Innovation Funds around its initial public offering. On April 20, 2026, these reporting persons completed an open‑market purchase of 235,294 shares of Common Stock at $17.00 per share, held indirectly, bringing one reported Common Stock position to 507,076 shares following the transaction.
At the same time, multiple convertible promissory notes and series of Preferred Stock automatically converted into Class B Common Stock, and each share of Class B Common Stock was then reclassified into one share of Common Stock in connection with the IPO. These conversions and a related reclassification moved millions of shares from preferred and Class B instruments into Common Stock, leaving no remaining balance in the reported derivative securities.
The securities are held by Illumina Innovation Fund II, L.P. and Illumina Innovation Fund III, L.P., whose general partners and sole managing member, director Nicholas Naclerio, may be deemed to have voting and investment power but each disclaims beneficial ownership except to any pecuniary interest.
Alamar Biosciences director Rebecca Chambers reported an internal restructuring of stock options, not an open-market trade. One option covering 140,612 shares of Common Stock at an exercise price of $7.60 per share is now recorded as outstanding, while a corresponding option tied to 140,612 shares of Class B Common Stock was removed.
Each share of Class B Common Stock was reclassified into one share of Common Stock immediately before the company’s initial public offering, and the option reflects that change. Twenty-five percent of the option vests on January 15, 2027, with the remaining shares vesting in equal monthly installments over the following three years, and the option expires on January 14, 2036.
Alamar Biosciences director Frank Witney reported internal option restructurings related to the company’s share reclassification. On April 20, 2026, six Form 4 transactions with code J moved stock options between underlying Class B Common Stock and Common Stock at no transaction price.
The filing shows options for 124,069 shares at an exercise price of $7.60 expiring on January 14, 2036, 33,085 shares at $3.10 expiring on April 15, 2035, and 49,627 shares at $0.59 expiring on April 20, 2031. A footnote states each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering.
Alamar Biosciences President Timothy Ogden White reported equity awards and restructuring of his holdings in connection with the company’s initial public offering. On April 20, 2026, he received 37,220 shares of Common Stock as restricted stock units that vest monthly, bringing his direct Common Stock holdings to 491,803 shares.
The filing also shows multiple Class B Common Stock and related stock options being reclassified into equivalent Common Stock immediately prior to completion of the IPO, with no cash changing hands. Separately, on April 16, 2026, he was granted a stock option for 163,358 shares of Common Stock at an exercise price of $17.00 per share, vesting over time beginning in 2027.
Alamar Biosciences Chief Operating Officer Shiping Chen reported equity compensation grants and pre‑IPO share conversions, with no open‑market buying or selling. Chen received 37,220 shares of Common Stock as restricted stock units that vest monthly, bringing direct Common Stock holdings to 760,105 shares after the award.
The filing also shows automatic conversions of Class A Common Stock, Founders Preferred Stock, Series A‑1 Preferred Stock and Class B Common Stock into Common Stock immediately before Alamar’s IPO, plus administrative reclassifications of related stock options. Chen was granted a new stock option over 163,358 shares at $17.00 per share, alongside existing options with lower exercise prices.
Alamar Biosciences CEO Yuling Luo reported a series of equity restructurings and awards around the company’s initial public offering. Several classes of preferred and Class A shares automatically converted into Class B Common Stock and were then reclassified into Common Stock immediately before the IPO, with no cash changing hands.
The filing also shows a grant of 76,509 restricted stock units that vest monthly, and a new stock option for 341,191 shares of Common Stock at an exercise price of $17.00 per share, vesting over four years. Many option entries reflect technical reclassifications between Class B Common Stock and Common Stock rather than market trades.
Alamar Biosciences Chief Financial Officer Justin J. McAnear reported new equity awards and an option restructuring. He received 37,220 shares of Common Stock as restricted stock units that vest monthly from the grant date, conditioned on his continued service.
He was also granted stock options for 163,358 shares of Common Stock at an exercise price of $17.00 per share, with 25% vesting on April 16, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continued service. In addition, 570,719 stock options with a $4.62 exercise price were reclassified so the underlying security changed from Class B Common Stock to Common Stock in connection with the company’s initial public offering, with no open-market buying or selling reported.
Alamar Biosciences director Nicholas Naclerio reported multiple equity-related transactions. An entity associated with him purchased 235,294 shares of Common Stock at $17.00 per share, increasing indirect ownership. He also received 5,686 restricted stock units that vest in three equal installments on April 20, 2027, April 20, 2028 and April 20, 2029, contingent on continued service.
In addition, he was granted a stock option for 25,599 shares at an exercise price of $17.00 per share, vesting from April 16, 2027 through April 16, 2029 and expiring on April 15, 2036. Several series of Preferred Stock and a convertible promissory note held by Illumina Innovation Fund entities automatically converted into Class B Common Stock, which was then reclassified into Common Stock in connection with the company’s IPO, with Naclerio disclaiming beneficial ownership except for his pecuniary interests.